Aurinia Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary

Aurinia Pharmaceuticals

31/07/2025 14:31

Aurinia Pharmaceuticals Inc AUPH.OQ reported quarterly adjusted earnings of 16 cents​​ per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of 1 cents.  The mean expectation of six analysts for the quarter was for earnings of 15 cents per share. Wall Street expected results to range from 11 cents to 20 cents per share.

Revenue rose 22.4% to $70.01 million from a year ago; analysts expected $63.70 million.

Aurinia Pharmaceuticals Inc's reported EPS for the quarter was 16 cents​.

The company reported quarterly net income of $21.51 million.

Aurinia Pharmaceuticals Inc shares had risen by 6.8% this quarter and gained 0.8% so far this year.

FORECAST CHANGES

The mean earnings estimate of analysts had risen by about 35.8% in the last three months.​

In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

Wall Street's median 12-month price target for Aurinia Pharmaceuticals Inc is $10.85, about 16.6% above its last closing price of $9.05

This summary was machine generated from LSEG data July 31 at 01:31 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

QUARTER ENDING
ESTIMATE
ACTUAL
BEAT, MET, MISSED
Jun. 30 2025
0.15
0.16
Beat
Mar. 31 2025
0.10
0.16
Beat
Dec. 31 2024
-0.02
0.01
Beat
Sep. 30 2024
0.02
0.10
Beat